Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,274 total articles
HealthEquity has built a compounding business where account growth, HSA asset inflows and HSA investment adoption feed higher fee revenue and free cash flow. Recent metrics show accelerating assets and record sales, while the stock trades on a reasonable multiple given steady FCF. This trade idea sets a disciplined long entry with a clear stop and …
Rigetti (RGTI) popped hard after the U.S. awarded a $100M CHIPS-era grant and took a minority equity stake. The cash and political endorsement materially extend runway and refocus sentiment—creating a high-risk swing trade. Entry $27.71, stop $21.00, target $38.00; watch volatility, dilution risk, and revenue execution closely.
SCZ, the iShares MSCI EAFE Small-Cap ETF, is trading above its short-term moving averages with a 2.6% yield, a modest PE of 19.3 and a PB of 1.61. With the fund sitting near its 52-week high and technical support at the 20/50-day SMAs, a disciplined long trade captures income, the potential for multiple expansion and the chance of a short-covering …
The Trade Desk (TTD) has been punished for slowing growth and weak guidance. The market has largely sold first and asked questions later: share price is back near the low of the year, valuation has compressed to attractive levels relative to growth expectations, and free cash flow remains healthy. This trade idea outlines a clear long entry at $22.…
Sika's market pullback creates a tactical buying window under 150 CHF (about $165). The company’s resilient exposure to construction and renovation, strong product mix and pricing power argue for upside once macro uncertainty and cyclical weakness ease. This trade is structured as a mid-term swing: entry $165.00, target $195.00, stop loss $150.00. …
Snowflake (SNOW) is trading well below last year's highs despite clear positioning as the enterprise data layer for AI. Technicals and flow suggest buyers are stepping in; fundamentals show strong free cash flow and a large market opportunity. This trade idea lays out an exact entry, stop, and target with horizon-specific plans and a balanced risk …
CF Industries is a top-tier nitrogen fertilizer producer trading at a reasonable multiple versus cyclicality and generating significant free cash flow. With global supply volatility, an attractive FCF yield and a path into higher-margin green ammonia, this is a tactical long trade with defined risk controls.
Tapestry (TPR) is trading near $139 after a period of consolidation. Strong free cash flow, a massive $2.8B buyback program in 2025, and steady brand fundamentals support a tactical long. Entry at $139.31, stop at $128.00 and a primary target of $160.00 reflect a risk-managed trade over the next 45-180 trading days.
Nebius Group (NBIS) has turned into one of the fastest-growing, profitable pure-plays in AI infrastructure. With Q1 revenue momentum, a new Bloom Energy power partnership, and strategic backing from Nvidia, the company offers asymmetric upside despite a premium valuation. This trade plan buys a measured long position at current levels with a clear …
Vermilion Energy has doubled from its 52-week low and still carries a respectable dividend and a sub-$2B market cap, but momentum has turned cautious and short interest has crept higher. We downgrade to neutral and recommend a tactical profit-taking trade: enter at the market, target $11.00, stop $12.90, horizon 10 trading days.
Agnico Eagle (AEM) has pulled back sharply from its year-to-date highs. The stock now trades at $174.57, offering a mid-term swing opportunity: a disciplined entry at current levels, a tight stop below $160, and a target near $205. Fundamentals — low-cost mines, a growing asset base in Finland and a healthy market cap of $87.5B — support upside if …
Nano Labs (NA) trades at a tiny $62.7M market cap, a P/E of 2.67 and P/B of 0.54 despite possession of AI-focused chips, a North America AI data-center MOU and a CEO share buy. Elevated short interest and recent product noise have left the stock depressed; a structured mid-term long (45 trading days) captures potential re-rating while limiting down…
Roper Technologies (ROP) is a diversified acquirer of vertical software and niche hardware businesses. With $2.55B in free cash flow, a conservative balance sheet (debt/equity ~0.56) and 33+ years of dividend raises, the stock looks attractive around $325 for a long trade that bets on reacceleration via tuck-in M&A and multiple expansion as earning…
ATI Inc. ($ATI) is a high-quality specialty materials compounder benefiting from higher aircraft production, aftermarket growth, and long-term demand for titanium and nickel alloys. At $161.08 the stock looks priced for growth but not frothy given 24% ROE, $552.5M in free cash flow, and a $22B market cap. This trade targets continued operational le…
Micron's business is capturing robust AI memory demand, generating meaningful free cash flow, and trading well above its multi-year lows. Valuation looks rich versus history but is supported by strong profitability and low leverage. This trade idea sets a long-term (180 trading days) plan with entry at $760, target $1,000 and a stop at $650 to bala…
Southern Company (SO) combines a conservative regulated utility base with growing wholesale and gas platforms that stand to benefit from accelerated data center and AI-related electricity demand. Recent beats, reaffirmed guidance, and a visible dividend raise underscore operational resilience. Valuation is not cheap for a utility, but rate-base exp…
United Microelectronics (UMC) is showing the technical, strategic and sentiment signs of a re-rating. Recent IP deals around hybrid bonding, a U.S. 8-inch collaboration and merger chatter have shifted investor expectations away from a low-growth, mature-node foundry story. This trade recommends a measured long with an entry at the current level, a …
Alphabet is not SpaceX, but for investors who want pre-IPO exposure to the private space economy without illiquidity or lock-ups, buying Alphabet shares is a defensible, actionable strategy. Alphabet's scale, cash generation, cloud franchise and 'Other Bets' optionality make it a plausible conduit for indirect upside if a SpaceX IPO or strategic pa…
Hercules Capital (HTGC) is trading near $15.52 after a headline-driven sell-off. The stock yields roughly 10% on the current distribution cadence, trades at ~P/E 8.6 and P/B ~1.31, and sits well below its 52-week high. We lay out a mid-term trade plan to buy the dip with a clear entry, stop and target, and discuss the key risks — including active l…
argenx's FcRn platform (VYVGART and Hytrulo) is transitioning from a single blockbuster to a multi-indication backbone across neuromuscular and peripheral autoimmune diseases. FDA label expansion, strong Phase 3 readouts, and a clear commercial ramp argue for continued upside from today's $817 share price, but execution and competition keep risk el…
Rocket Lab (RKLB) has a rare alignment of fundamentals, backlog growth and market sentiment as SpaceX prepares to IPO. The technical setup is constructive and short-interest dynamics amplify upside. This trade plan lays out a clear entry at $129.62, a stop at $110.00 and a primary target of $170.00 over a mid-term 45 trading day horizon.
Arista's Q1 beat, raised AI revenue target and strong free cash flow argue that the recent selloff over margin pressure is an opportunity. This trade idea targets a bounce back toward prior highs as AI data-center demand remains intact; entry $150.00, stop $138.00, target $180.00, mid-term horizon (45 trading days).
Paramount-Skydance (PARA) is positioned to accelerate subscriber and advertising momentum after combining a deep content library with Skydance's production capabilities. We outline an actionable swing trade: entry $22.50, stop $19.00, target $28.00, with a longer-term upside target at $35.00 if execution and monetization accelerate.
VEON trades at a sub-$4B market cap with a P/E of ~7.3 and growing digital revenues ($759M in 2025). The stock offers an asymmetric risk-reward if you accept frontier-country execution and macro risk. This trade lays out entry, stop and target with a 180-trading-day horizon and clear rules for when the thesis fails.
Zymeworks ($ZYME) combines royalty revenue from licensed assets with a deep antibody-drug conjugate (ADC) pipeline that now carries real clinical momentum. The market prices the company like a high-growth commercial biopharma at a $1.85B market cap, but cash-like royalties, recent leadership hires aligned with deal execution, and Fast Track status …
